Myriad Genetics (MYGN) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Myriad Genetics (MYGN) PT Raised to $23 at Jefferies
August 9, 2017 8:40 AM EDTJefferies raised its price target on Myriad Genetics (NASDAQ: MYGN) to $23.00 (from $21.00) while maintaining a Hold rating. MYGN's initial FY18 revenue outlook fell ~$30M below consensus, owing to ASP headwinds it will absorb in hereditary cancer from steps taken to secure LT, fixed-price... More
